ATLANTA, GA / ACCESSWIRE / May 5, 2022 / Holzer & Holzer, LLC is investigating whether HUTCHMED Limited ("HUTCHMED" or the "Company") (NASDAQ:HCM) complied with federal securities laws. On May 2, 2022, HUTCHMED announced that the FDA issued a Complete Response Letter regarding its New Drug Application. According to HUTCHMED, the FDA determined that the Company's current data package does not support approval in the U.S. and that a multi-regional clinical trial that includes subjects more representative of the U.S. patient population is required. Following this announcement, the Company's stock price dropped.
If you purchased HUTCHMED stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
SOURCE: Holzer & Holzer